Literature DB >> 10791215

The role of vitamin D3 receptor mRNA in the proliferation of hepatocellular carcinoma.

S Miyaguchi1, T Watanabe.   

Abstract

BACKGROUND/AIMS: 1,25-Dihydroxyvitamin D3 [1,25-(OH)2D3] exhibits effects on cell proliferation and differentiation.
METHODOLOGY: We examined the anti-proliferative effect of 1,25-(OH)2D3 on human hepatocellular carcinoma cell lines (PLC/PRF/5, HCC-T) and the role of vitamin D receptors in modulating this effect. We also investigated the gene expression of vitamin D receptors in tissues from patients with hepatocellular carcinoma.
RESULTS: 1,25-(OH)2D3 inhibited proliferation of PLC/PRF/5 cells that express prominent vitamin D receptor mRNA with time and dose dependent manner. On the other hand 1,25-(OH)2D3 had no anti-proliferative effect on hepatocellular carcinoma T cells in which gene expression of vitamin D receptor was little. We next examined vitamin D receptor gene expression in surgically obtained 10 hepatocellular carcinoma tissues by reverse transcriptase-polymerase chain reaction analysis. In all 10 cases, the level of vitamin D receptor mRNA in tumorous tissue was expressed on tumorous tissue.
CONCLUSIONS: These results indicate that 1,25-(OH)2D3 may clinically exert its anti-proliferative effect through vitamin D receptors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10791215

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  5 in total

1.  Helicobacter hepaticus--induced liver tumor promotion is associated with increased serum bile acid and a persistent microbial-induced immune response.

Authors:  Alexis García; Yu Zeng; Sureshkumar Muthupalani; Zhongming Ge; Amanda Potter; Melissa W Mobley; Chakib Boussahmain; Yan Feng; John S Wishnok; James G Fox
Journal:  Cancer Res       Date:  2011-02-18       Impact factor: 12.701

2.  Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies.

Authors:  Robert Wieder; Steven C Novick; Bruce W Hollis; Margarette Bryan; Suzanne M Chanel; Kate Owusu; Danielle Camastra; Tracie Saunders; Lillian Pliner; Jonathan Harrison; Peter Bonate; Tom Williams; Steven Soignet
Journal:  Invest New Drugs       Date:  2003-11       Impact factor: 3.850

Review 3.  Current therapies in alleviating liver disorders and cancers with a special focus on the potential of vitamin D.

Authors:  Shahida Khan; Ashraf Ali; Sarah Khan; Ahmed Bakillah; Ghazi Damanhouri; Aziz Khan; Ahmad Makki; Ibtehal AlAnsari; Naheed Banu
Journal:  Nutr Metab (Lond)       Date:  2018-02-09       Impact factor: 4.169

4.  Vitamin D reverts resistance to the mTOR inhibitor everolimus in hepatocellular carcinoma through the activation of a miR-375/oncogenes circuit.

Authors:  Donatella Paola Provvisiero; Mariarosaria Negri; Cristina de Angelis; Gilda Di Gennaro; Roberta Patalano; Chiara Simeoli; Fortuna Papa; Rosario Ferrigno; Renata Simona Auriemma; Maria Cristina De Martino; Annamaria Colao; Rosario Pivonello; Claudia Pivonello
Journal:  Sci Rep       Date:  2019-08-12       Impact factor: 4.379

5.  A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma.

Authors:  K Dalhoff; J Dancey; L Astrup; T Skovsgaard; K J Hamberg; F J Lofts; O Rosmorduc; S Erlinger; J Bach Hansen; W P Steward; T Skov; F Burcharth; T R J Evans
Journal:  Br J Cancer       Date:  2003-07-21       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.